Supernus Pharmaceuticals (SUPN) FCF Margin (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly FCF Margin of 2.46% for Q2 2026, down 3756.0% year-over-year from 0.07% in Q2 2025, and down 126.73% on a QoQ basis from 9.19% in Q4 2025.
Supernus Pharmaceuticals (SUPN) FCF Margin (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported FCF Margin for 16 years, with the latest figure at 2.46% in Q2 2026.
- FCF Margin for Q2 2026 came in at 2.46%, down 3756.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 2.38% (down 2556.0% YoY), and the FY2025 annual result was 6.4%, down 1947.0% from the prior year.
- FCF Margin retreated to 2.46% in Q2 2026, from 9.19% in the prior quarter.
- Over five years, FCF Margin peaked at 41.98% in Q2 2022 and troughed at 32.17% in Q3 2025.
- A 5-year average of 15.9% and a median of 21.13% in 2024 frame the typical range for FCF Margin.
- The widest annual swing landed in 2024, when FCF Margin jumped 3517 bps; it then plunged 6252 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 16.57% in 2022, then jumped by 65 bps to 27.38% in 2023, then fell by 7 bps to 25.38% in 2024, then slumped by 64 bps to 9.19% in 2025, then tumbled by 127 bps to 2.46% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 2.46% in Q2 2026, 9.19% in Q4 2025, and 32.17% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.41% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 21.80% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 14.87% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 26.25% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 8.76% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 13.41% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 17.84% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | -2.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.46% |
| Dec 31, 2025 | 9.19% |
| Sep 30, 2025 | -32.17% |
| Jun 30, 2025 | 35.10% |
| Mar 31, 2025 | 20.21% |
| Dec 31, 2024 | 25.38% |
| Sep 30, 2024 | 30.35% |
| Jun 30, 2024 | 21.13% |
| Mar 31, 2024 | 26.56% |
| Dec 31, 2023 | 27.38% |
| Sep 30, 2023 | 23.22% |
| Jun 30, 2023 | -14.04% |
| Mar 31, 2023 | 31.77% |
| Dec 31, 2022 | 16.57% |
| Sep 30, 2022 | 7.80% |
| Jun 30, 2022 | 41.80% |
| Mar 31, 2022 | 2.46% |
| Dec 31, 2021 | 30.66% |
| Sep 30, 2021 | -2.77% |
| Jun 30, 2021 | 32.74% |